MIB1 and skull base meningioma: The intake of low-dose ASA (adjusted odds ratio (OR): 2.60, 95% confidence interval (CI): 1.03–6.55, p = 0.04) was independently and significantly associated with a decreased MIB-1 labeling index (<5%) in female non-skull-base meningioma patients aged 60 years or older.